Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), has emerged as a significant focus in clinical research due to its increasing prevalence and potential for severe liver complications. As a clinical trial company, we are at the forefront of researching innovative treatments for this complex condition.

While both conditions affect the esophagus, they have distinct causes, symptoms, and treatments. Let's explore these conditions and how our research aims to make a difference.